LogicBio Therapeutics Inc (LOGC)

NASDAQ
4.580
+0.250(+5.77%)
  • Volume:
    100,821
  • Bid/Ask:
    4.300/4.570
  • Day's Range:
    4.300 - 4.580

LOGC Overview

Prev. Close
4.33
Day's Range
4.3-4.58
Revenue
2.89M
Open
4.32
52 wk Range
3.72-9.745
EPS
-1.24
Volume
100,821
Market Cap
147.29M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
190,742
P/E Ratio
-
Beta
-
1-Year Change
-43.18%
Shares Outstanding
32,160,459
Next Earnings Date
Aug 17, 2021
What is your sentiment on LogicBio Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

LogicBio Therapeutics Inc News

LogicBio Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyBuyStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell

LogicBio Therapeutics Inc Company Profile

LogicBio Therapeutics Inc Company Profile

Employees
39

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company’s lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.